Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group. Dubsky PC, et al. Eur J Cancer. 2020 Jul;134:99-106. doi: 10.1016/j.ejca.2020.04.020. Epub 2020 Jun 2. Eur J Cancer. 2020. PMID: 32502940 Free article. Clinical Trial.
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Bago-Horvath Z, et al. Clin Cancer Res. 2011 Dec 15;17(24):7828-34. doi: 10.1158/1078-0432.CCR-11-1846. Epub 2011 Oct 13. Clin Cancer Res. 2011. PMID: 21998336
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.
Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H, Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, Schlake G, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, Kerjaschki D, Sinn BV, Müller BM, Filipits M, Petry C, Dietel M. Denkert C, et al. Virchows Arch. 2012 Mar;460(3):251-9. doi: 10.1007/s00428-012-1204-4. Epub 2012 Feb 28. Virchows Arch. 2012. PMID: 22371223 Free PMC article.
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Filipits M, et al. Clin Cancer Res. 2014 Mar 1;20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11. Clin Cancer Res. 2014. PMID: 24520097
Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging.
Pinker K, Bogner W, Baltzer P, Gruber S, Bickel H, Brueck B, Trattnig S, Weber M, Dubsky P, Bago-Horvath Z, Bartsch R, Helbich TH. Pinker K, et al. Invest Radiol. 2014 Jun;49(6):421-30. doi: 10.1097/RLI.0000000000000029. Invest Radiol. 2014. PMID: 24566292
96 results